Search results for "Side effects"
Multiple agents effective for excessive daytime sleepiness but may be discontinued due to side effects, review finds
A systematic review and meta-analysis of 14 trials found that solriamfetol, armodafinil-modafinil, and pitolisant were associated with reduced daytime sleepiness but also with headache, insomnia, and anxiety in patients with obstructive sleep apnea.
https://immattersacp.org/weekly/archives/2023/05/09/1.htm
9 May 2023
Closing the gap on osteoporosis
A new clinical guideline from ACP focuses on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults.
https://immattersacp.org/archives/2023/05/closing-the-gap-on-osteoporosis.htm
1 May 2023
Experts offer optimism on overcoming obesity
ACP and Annals of Internal Medicine hosted a forum on managing the epidemic levels of obesity in America.
https://immattersacp.org/archives/2023/05/experts-offer-optimism-on-overcoming-obesity.htm
1 May 2023
Stepping up to treat osteoporosis
This month's issue addresses osteoporosis, transient ischemic attacks, and another edition of I.M. Ready columns for early career physicians.
https://immattersacp.org/archives/2023/05/stepping-up-to-treat-osteoporosis.htm
1 May 2023
Dabigatran recalled, dense-breast notification required
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/05/dabigatran-recalled-dense-breast-notification-required.htm
1 May 2023
Over-the-counter test for flu, COVID-19 authorized
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/04/over-the-counter-test-for-flu-covid-19-authorized.htm
1 Apr 2023
Separate industry-funded studies find benefit to bempedoic acid as preventive medication, CRP as biomarker
Bempedoic acid reduced cardiovascular (CV) events among patients unwilling or unable to take statins, a trial found, while a review showed that high-sensitivity C-reactive protein (CRP) was a stronger predictor for risk of future CV events and death than cholesterol in patients on statins.
https://immattersacp.org/weekly/archives/2023/03/14/4.htm
14 Mar 2023
Hydrochlorothiazide no better than placebo for preventing kidney stone recurrence
A randomized, double-blind, placebo-controlled trial in Switzerland found that patients with a history of recurring kidney stones were no less likely to experience symptomatic or radiologic recurrence with hydrochlorothiazide versus placebo.
https://immattersacp.org/weekly/archives/2023/03/07/1.htm
7 Mar 2023
Combo treatment approved for asthma
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/03/combo-treatment-approved-for-asthma.htm
1 Mar 2023
Getting to know GLP-1 receptor agonists
Choosing among glucagon-like peptide-1 (GLP-1) receptor agonists depends on many factors, such as the desired outcome and individual risks among patients.
https://immattersacp.org/archives/2023/03/getting-to-know-glp-1-receptor-agonists.htm
1 Mar 2023